Teva Pharmaceutical Industries Limited
TEVA | NYSE
$39.23
-$0.83 (-2.07%)
Sep 22, 2026, 1:31 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 25.37 | -15.20 | -20.88 | -4.15 | 21.08 | -2.65 |
PEG Ratio | -0.14 | -0.08 | 0.27 | 0.01 | -0.19 | -0.01 |
PS Ratio | 2.08 | 1.51 | 0.74 | 0.68 | 0.56 | 0.63 |
PB Ratio | 4.53 | 4.64 | 1.56 | 1.30 | 0.86 | 1.05 |
P/FCF Ratio | 31.24 | 33.28 | 13.87 | 9.72 | 37.40 | 16.56 |
P/OCF Ratio | 21.75 | 19.99 | 8.54 | 6.37 | 11.06 | 8.69 |
OCF/S Ratio | 9.56 | 7.54 | 8.63 | 10.65 | 5.03 | 7.30 |
Debt / Equity Ratio | 2.20 | 3.36 | 2.68 | 2.76 | 2.28 | 2.63 |
Quick Ratio | 0.80 | 0.75 | 0.69 | 0.72 | 0.79 | 0.65 |
Current Ratio | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 |
Asset Turnover | 0.42 | 0.42 | 0.36 | 0.34 | 0.33 | 0.33 |
Interest Coverage | 2.35 | -0.32 | 0.42 | -2.36 | 1.93 | -4.73 |
Return on Equity | 17.83% | -30.50% | -7.45% | -31.34% | 4.06% | -39.80% |
Return on Assets | 3.46% | -4.17% | -1.29% | -5.56% | 0.87% | -7.88% |
Return on Invested Capital | 7.41% | -1.07% | 1.30% | -5.04% | 3.08% | -8.78% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% | 46.38% |
Net Profit Margin | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% | -23.95% |
Pretax Profit Margin | 7.17% | -7.76% | -3.93% | -21.05% | 4.20% | -23.60% |
Operating Profit Margin | 12.50% | -1.83% | 2.73% | -14.72% | 10.81% | -21.44% |
FCF Margin | 6.65% | 4.53% | 5.31% | 6.98% | 1.49% | 3.83% |
EBITDA Margin | 18.20% | 26.78% | 9.83% | -6.20% | 27.77% | 27.68% |
Add to Watchlist
Select watchlists to add or remove TEVA